Program
surovatamig
Also written as “Surovatamig”, “AZD0486” and “AZD0486 IV”.
Its studies are mostly in Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell · Arthritis, Rheumatoid · Lymphoma, Follicular · Glomerulonephritis, Membranous, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 1010 open or running | phase 3since Jul 29, 2024 | Oct 13, 2020 | Jan 6, 2028phase 2 · NCT06137118 |
- Named in AstraZeneca’s own pipeline as
surovatamig
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2020First study: phase 1 study in Lymphoma, B-CellFirst studyNCT04594642 · 226 enrolled · United States, Australia, Japan and more
- Nov 3, 2023Phase 2 study in Burkitt LymphomaNCT06137118 · 255 planned · United States, Australia, Brazil and more
- Jul 3, 2024Phase 2 study in Lymphoma, B-CellNCT06526793 · 270 planned · United States, Australia, Brazil and more
- Jul 29, 2024Phase 3 study in Lymphoma, FollicularNCT06549595 · 1,018 planned · United States, Australia, Belgium and more
- Aug 19, 2024Phase 2 study in Leukemia, B-CellNCT06564038 · 408 planned · United States, Australia, China and more
- Sep 30, 2025Phase 1 study in Arthritis, RheumatoidNCT07201558 · 48 planned · United States, Australia, Belgium and more
- Oct 7, 2025Phase 3 study in Large B-cell LymphomaNCT07215585 · 420 planned · Australia, Belgium, Brazil and more
- Mar 19, 2026Phase 2 study in Primary Membranous NephropathyNCT07571746 · 43 planned · United States, Belgium, China and more
- Mar 27, 2026Phase 3 study in Leukemia, B-CellNCT07509151 · 420 planned · United States, Australia, Canada and more
- Oct 20, 2026Primary completion moved from 2028-04-24 to 2028-10-13Date moved laterphase 2 · +6 months · NCT07571746
- Oct 26, 2026Phase 3 study in Lymphoma, B-CellNCT07911553 · 1,200 planned
- Oct 28, 2026Primary completion moved from 2029-06-11 to 2030-05-20Date moved laterphase 2 · +11 months · NCT06564038
Ahead
- Jan 6, 2028Primary completion: phase 2 study in Burkitt LymphomaNCT06137118
- Apr 21, 2028Primary completion: phase 2 study in Lymphoma, B-CellNCT06526793
- Jun 19, 2028Primary completion: phase 1 study in Lymphoma, B-CellNCT04594642
- Jun 27, 2028Primary completion: phase 1 study in Arthritis, RheumatoidNCT07201558
TargetBeta
“A human bispecific T-cell engager antibody composed of a fixed-light-chain (FLC) arm targeting the CD3 antigen found on T-lymphocytes and a heavy-chain-only (HCO) arm targeting the B-cell-specific membrane protein CD19, with potential immunostimulating and antineoplastic activities. Upon administ…”NCIt, read by Claude
“A human bispecific T-cell engager antibody composed of a fixed-light-chain (FLC) arm targeting the CD3 antigen found on T-lymphocytes and a heavy-chain-only (HCO) arm targeting the B-cell-specific membrane protein CD19, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| YK012rule | excyte-biopharma-ltd | phase 2 | 5 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rule | cullinan-therapeutics-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rule | cytocares-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 3 |
| ATG-201rule | antengene-biologics-limited | phase 1 | 1 |
| KT501rule | kali-therapeutics-inc | phase 1 | 1 |
| KT502rule | kali-therapeutics-inc | phase 1 | 1 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07911553Lymphoma, B-Cell | 3 | Not yet recruiting | Sep 2, 2030 | 1,200 |
| NCT07509151Leukemia, B-Cell · United States, Australia, Canada and more | 3 | Recruiting | Aug 29, 2031 | 420 |
| NCT07571746Primary Membranous Nephropathy · United States, Belgium, China and more | 2 | Recruiting | Oct 13, 2028 | 43 |
| NCT07215585Large B-cell Lymphoma · Australia, Belgium, Brazil and more | 3 | Recruiting | Jun 10, 2030 | 420 |
| NCT07201558Arthritis, Rheumatoid · United States, Australia, Belgium and more | 1 | Recruiting | Jun 27, 2028 | 48 |
| NCT06564038Leukemia, B-Cell · United States, Australia, China and more | 2 | Recruiting | May 20, 2030 | 408 |
| NCT06549595Lymphoma, Follicular · United States, Australia, Belgium and more | 3 | Recruiting | Nov 26, 2031 | 1,018 |
| NCT06526793Lymphoma, B-Cell · United States, Australia, Brazil and more | 2 | Recruiting | Apr 21, 2028 | 270 |
| NCT06137118Burkitt Lymphoma · United States, Australia, Brazil and more | 2 | Recruiting | Jan 6, 2028 | 255 |
| NCT04594642Lymphoma, B-Cell · United States, Australia, Japan and more | 1 | Active, not recruiting | Jun 19, 2028 | 226 |
How it is read
Names in the registry
- “Surovatamig”, 8 entries
- “AZD0486”, 1 entry
- “AZD0486 IV”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, B-Cell, 3 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
- Arthritis, Rheumatoid, 1 study
- Lymphoma, Follicular, 1 study
- Glomerulonephritis, Membranous, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.